Core Insights - The company, founded in 2010, focuses on cardiac electrophysiology, aiming to introduce advanced arrhythmia treatment solutions to China and serve patients effectively [1] - The company has achieved significant milestones, including the development of the first domestic and third global magnetic positioning three-dimensional cardiac electrophysiology system, breaking the reliance on imports in this field [2] - The company went public on the Sci-Tech Innovation Board in 2022, marking a new chapter in its development and emphasizing its commitment to technological innovation [2] Company Development - The company has made substantial investments in research and development, resulting in the successful launch of several high-end products, including a domestic cryoablation system and various catheter technologies [2] - The company has established a comprehensive treatment platform that integrates "radiofrequency, cryo, and pulsed" technologies, providing a wider range of quality options for clinical applications [2] - The company has gained recognition as a high-tech enterprise, with its products widely used in major hospitals across China and exported to over 30 countries and regions globally [2] Future Outlook - The company plans to continue its strategy of "technological breakthroughs and global development," focusing on deepening its presence in the cardiac electrophysiology field and launching more innovative products and solutions [3] - The company aims to enhance its global business layout and contribute to the high-quality development of China's medical device industry [3]